{"id":2185991,"date":"2022-06-07T19:47:00","date_gmt":"2022-06-07T17:47:00","guid":{"rendered":"http:\/\/nhub.news\/?p=2185991"},"modified":"2022-06-08T03:58:08","modified_gmt":"2022-06-08T01:58:08","slug":"can-new-covid-vaccine-win-over-the-anti-vaxxers","status":"publish","type":"post","link":"http:\/\/nhub.news\/fr\/2022\/06\/can-new-covid-vaccine-win-over-the-anti-vaxxers\/","title":{"rendered":"Can new COVID vaccine win over the anti-vaxxers?"},"content":{"rendered":"<p style=\"text-align: justify;\"><b>Designed using traditional approach, Novavax vaccine gets review by FDA advisory panel on Tuesday.<\/b><br \/>\nWith three COVID vaccines already authorized by the U.S. Food and Drug Administration, Americans have easy access to plenty of shots. But a fourth one, under review Tuesday, is entirely different \u2014 and it uses a traditional vaccine design that more people may be inclined to trust. The vaccine, made by Novavax, works just as well as the Pfizer and Moderna vaccines, the company\u2019s studies show. Its side effects seem milder. It\u2019s easier to store. At least 41 other countries \u2014 including Australia, Canada, South Korea and the 27 members of the European Union \u2014 have approved it. And it enlists the same familiar technique as vaccines against flu, diphtheria, tetanus and whooping cough.<br \/>\u201cI\u2019m likely going to recommend this for my parents, who are age 84 and 87, for their fifth dose this fall,\u201d said UC San Francisco infectious disease specialist Dr. Monica Gandhi. It may also bolster immunity when used in combination with existing vaccines, said infectious disease expert Dr. Peter Chin-Hong of UCSF. While not yet proven, the Novavax vaccine\u2019s use as a booster could trigger the production of a broader array of antibodies, which might help fend off new variants.<br \/>\u201cI think it would make good sense to \u2018mix and match\u2019 with a completely different type of vaccine,\u201d he said. \u201cIt may generate new kinds of antibodies than are in mRNA vaccines.\u201d<br \/> On Tuesday, the vaccine must pass a critical milestone when a panel of outside experts will recommend \u2014 or reject \u2014 that the FDA authorize the vaccine. Data show that Novavax is 96% effective in preventing severe disease or death and 90% protective against infection, comparable to Moderna and Pfizer. This data was collected before the more contagious omicron and its subvariants started widely circulating. About 40% of people reported fatigue after a second dose of Novavax, compared with 65% for Moderna and more than 55% percent for Pfizer. But there are concerns about a small number of cases of rare heart inflammation, which caused the biotech company\u2019s share price to plummet 18% on Monday. Similar problems led federal health officials this spring to recommend a pause in the use of Johnson &#038; Johnson\u2019s vaccine. While the new vaccine\u2019s arrival is too late to make an impact against the deadly early waves of the COVID pandemic, it could make inroads among the unvaccinated. About one-quarter of Americans age 18 and older are not yet fully vaccinated.<br \/>\u201cThe mRNA vaccines that we have in this country are great. But we need another vaccine that\u2019s more traditional,\u201d said Gandhi. \u201cIt\u2019s something that people are used to, and they\u2019ve seen before.\u201d<br \/> Cases of COVID continue to climb. As of Monday morning, the nation\u2019s toll reached 84,735,800 infections and 1,007,815 deaths \u2014 an increase of 213,572 and 616, respectively, from Friday.<br \/>\u201cI\u2019ve been waiting for this moment for a long time,\u201d said Heather Schmidt, of Ventura County, who is severely allergic to an ingredient in the available vaccines, so is unprotected. \u201cThis has been an incredibly stressful couple of years, and I really felt abandoned. I do not understand why every other country has more options than Americans.\u201d<br \/> Alan Chase, of Santa Cruz, newly diagnosed with COVID, said, \u201cI\u2019ve been waiting for the Novavax vaccine as my second booster shot. I figured the benefits of mixing and matching vaccines was worth waiting a bit longer. But alas, I waited too long and am now in bed. I\u2019ll still probably get it once available.\u201d<br \/> A fourth vaccine could also help control pharmaceutical price excesses, once vaccines are no longer free, said Art Caplan, a bioethicist and the founding director of the division of medical ethics at New York University\u2019s Grossman School of Medicine.<br \/>\u201cThere\u2019s going to be a need for some competition in the market,\u201d he said. Vaccines trigger the immune system by using an important piece of the COVID virus: the notorious spike protein. While the mRNA vaccines work by sending genetic instructions to the body to make copies of part of the spike protein, the Novavax vaccine takes a different approach. It contains the spike protein itself. (All alone, the spike protein is harmless and can\u2019t cause disease.) In essence, the Novavax vaccine offers a shortcut. Because it uses a bigger piece of the spike protein, which may be shared by more variants, it might help protect against newer versions of the evolving virus. Novavax is already designing a vaccine to combat the more infectious subtypes, but clinical data isn\u2019t expected until later this year. While Novavax will be a late entrant in the U.S. COVID vaccine marketplace, it has found international traction. The Trump administration\u2019s Operation Warp Speed program awarded Novavax a $1.6 billion contract for 100 million future doses, but the company was slow out of the gate. That\u2019s because manufacturer Novavax has little experience in the vaccine field, and its technology takes longer to test. This delayed its review by regulators. Related Articles<\/p>\n<p> National News| Coronavirus: Orange County is 71.9% fully vaccinated, June 6<\/p>\n<p> National News| Gov. Gavin Newsom tests positive for COVID-19<\/p>\n<p> National News| Why we need better COVID vaccines this fall<\/p>\n<p> National News| COVID-19 cases hit levels of past summer surges in California<\/p>\n<p> National News| Pfizer says 3 COVID shots protect children under 5\t In contrast, rivals Pfizer\/BioNTech and Moderna\/National Institutes of Health \u2014 who had the advantage of experience and powerful partnerships \u2014 quickly scored federal approval and now dominate the field. That\u2019s not because their vaccines are better; rather, they better managed their clinical trials. Use of J&#038;J vaccine has been greatly diminished. Novavax\u2019s inflammation data did not alarm UCSF\u2019s Chin-Hong, who noted that it was also seen in the placebo group and that other nations have not seen any dangerous signs. \u201cI think we need to understand that some more, to identify whether it is causal or not,\u201d he said. \u201cBut it doesn\u2019t worry me too much. It seems to be safe and well tolerated.\u201d<br \/>\u201cI welcome the vaccine just because it\u2019s an old fashioned method of using vaccines \u2014 and it may appeal to some people because of that,\u201d said Chin-Hong.<br \/>\u201cIs it going to move the needle among the unvaccinated in the U.S.? We\u2019ll probably convince a handful of more people to maybe think about\u201d getting vaccinated, he said. \u201cBut it probably will have more impact for the rest of the world.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Designed using traditional approach, Novavax vaccine gets review by FDA advisory panel on Tuesday. With three COVID vaccines already authorized by the U.S. Food and Drug Administration, Americans have easy access to plenty of shots. But a fourth one, under review Tuesday, is entirely different \u2014 and it uses a traditional vaccine design that more [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2185990,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[110],"tags":[],"_links":{"self":[{"href":"http:\/\/nhub.news\/fr\/wp-json\/wp\/v2\/posts\/2185991"}],"collection":[{"href":"http:\/\/nhub.news\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/nhub.news\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/nhub.news\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/nhub.news\/fr\/wp-json\/wp\/v2\/comments?post=2185991"}],"version-history":[{"count":0,"href":"http:\/\/nhub.news\/fr\/wp-json\/wp\/v2\/posts\/2185991\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/nhub.news\/fr\/wp-json\/wp\/v2\/media\/2185990"}],"wp:attachment":[{"href":"http:\/\/nhub.news\/fr\/wp-json\/wp\/v2\/media?parent=2185991"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/nhub.news\/fr\/wp-json\/wp\/v2\/categories?post=2185991"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/nhub.news\/fr\/wp-json\/wp\/v2\/tags?post=2185991"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}